Lilly fails to get Gemzar case before US Supreme Court

Bloomberg noted: The justices today [May 16] left intact a federal appeals court decision invalidating a patent that would have protected Gemzar from generic competition in the U.S. until May 2013.

Gemzar (generic name: gemcitabine) had sales of $723 million for Lilly in 2010.

See previous IPBiz post
ED Mich invalidates Lilly Gemzar patent